Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Ivanschitz

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Frontiers in Oncology|July 13, 2013
PML, SUMOylation, and SenescenceLisa Ivanschitz, Hugues De Thé, Morgane Le Bras
Proceedings of the National Academy of Sciences of the United States of America|November 19, 2015
PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescenceLisa Ivanschitz, Yuki Takahashi, Florence Jollivet, et al.
Cell Reports. Medicine|April 21, 2026
Debio 1562M CD37-targeting ADC is highly active and well tolerated in preclinical models of AML and MDSLéo Marx, Josée Hue-Perron, Alain Monjardet, et al.
Journal of Medicinal Chemistry|October 23, 2024
Structure-Guided Discovery of Selective USP7 Inhibitors with In Vivo ActivityAttila Vasas, Lisa Ivanschitz, Balázs Molnár, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Frontiers in Oncology|July 13, 2013
PML, SUMOylation, and SenescenceLisa Ivanschitz, Hugues De Thé, Morgane Le Bras
Proceedings of the National Academy of Sciences of the United States of America|November 19, 2015
PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescenceLisa Ivanschitz, Yuki Takahashi, Florence Jollivet, et al.
Cell Reports. Medicine|April 21, 2026
Debio 1562M CD37-targeting ADC is highly active and well tolerated in preclinical models of AML and MDSLéo Marx, Josée Hue-Perron, Alain Monjardet, et al.
Journal of Medicinal Chemistry|October 23, 2024
Structure-Guided Discovery of Selective USP7 Inhibitors with In Vivo ActivityAttila Vasas, Lisa Ivanschitz, Balázs Molnár, et al.
Pageof 1